Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate

• Published in: The oncologist (Dayton, Ohio)
• Main Authors: Moini, Katayoun, Seery, Tara, Nangia, Chaitali, MacDiarmid, Jennifer, Brahmbhatt, Himanshu, Spilman, Patricia, Sender, Lennie, Soon-Shiong, Patrick
• Format: Journal Article
• Language: English
• Published: England 04.10.2024
• Subjects: PD-L1 t-haNK; EDV-α-galactosyl ceramide; E-EDV-D682; N-803; metastatic pancreatic cancer

Multimodal temporal therapy orchestrated to leverage immunotherapy, tumor-targeted chemotherapy, and natural killer (NK) cell therapy may provide an opportunity to induce immunogenic cell death for tumor response and increased survival in patients with recurrent cancer. The interleukin-15 (IL-15) su...